Role of mitochondria in paricalcitol-mediated cytoprotection during obstructive nephropathy

American Journal of Physiology - Renal Physiology

Volumn 302, Issue 12, 2012, Pages

  García, Isabel Mercedes ^a   Altamirano, Liliana ^a   Mazzei, Luciana ^a   Fornés, Miguel ^b   Molina, Marisa Nile ^d   Ferder, León ^c   Manucha, Walter ^a,b  

^a Universidad Nacional de Cuyo Facultad de Ciencias Medicas   (Argentina)

^b Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

^c PONCE SCHOOL OF MEDICINE   (Puerto Rico)

^d Universidad Juan Agustin Maza   (Argentina)

Author keywords

Mitochondria; Obstructive nephropathy; Paricalcitol; Vitamin D receptor

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; MESSENGER RNA; PARICALCITOL; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4; VITAMIN D RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL NUCLEUS; CELL PROTECTION; CELL STRUCTURE; CONTROLLED STUDY; DENSITOMETRY; ELECTRON MICROSCOPY; ENZYME ACTIVITY; FEMALE; FLUORESCENCE; KIDNEY CORTEX; KIDNEY FIBROSIS; MITOCHONDRION; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; UNILATERAL URETER OBSTRUCTION; URETER OBSTRUCTION;

EID: 84862611448     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00617.2011     Document Type: Article

References (43)

1. Abadir PM, Foster DB, Crow M, Cooke CA, Rucker JJ, Jain A, Smith BJ, Burks TN, Cohn RD, Fedarko NS, Carey RM, O'Rourke B, Walston JD. Identification and characterization of a functional mitochon-drial angiotensin system. Proc Natl Acad Sci USA 108: 14849-14854, 2011.
2. Ago T, Matsushima S, Kuroda J, Zablocki D, Kitazono T, Sadoshima J. The NADPH oxidase Nox4 and aging in the heart. Aging (Albany NY) 2: 1012-1016, 2010.
3. Barreto FC, de Oliveira RA, Oliveira RB, Jorgetti V. Pharmacotherapy of chronic kidney disease and mineral bone disorder. Expert Opin Phar-macother 12: 2627-2640, 2011.
4. Crivello JF. Oxidative stress limits vitamin D metabolism by bovine proximal tubule cells in vitro. Arch Biochem Biophys 262: 471-480, 1988.
5. de Cavanagh EM, Ferder L, Toblli JE, Piotrkowski B, Stella I, Fraga CG, Inserra F. Renal mitochondrial impairment is attenuated by AT1 blockade in experimental Type I diabetes. Am J Physiol Heart Circ Physiol 294: H456-H465, 2008.
6. de Cavanagh EM, Inserra F, Ferder M, Ferder L. From mitochondria to disease: role of the renin-angiotensin system. Am J Nephrol 27: 545-553, 2007.
7. de Cavanagh EM, Toblli JE, Ferder L, Piotrkowski B, Stella I, Inserra F. Renal mitochondrial dysfunction in spontaneously hypertensive rats is attenuated by losartan but not by amlodipine. Am J Physiol Regul Integr Comp Physiol 290: R1616-R1625, 2006.
8. Dusso AS, Brown AJ. Mechanism of vitamin D action and its regulation. Am J Kidney Dis 32, Suppl 2: S13-S24, 1998.
9. Franklin RA, Rodriguez-Mora OG, Lahair MM, McCubrey JA. Activation of the calcium/calmodulin-dependent protein kinases as a consequence of oxidative stress. Antioxid Redox Signal 8: 1807-1817, 2006.
10. Gonzalez EA, Sachdeva A, Oliver DA, Martin KJ. Vitamin D insufficiency and deficiency in chronic kidney disease. A single center observational study. Am J Nephrol 24: 503-510, 2004.
11. Gorin Y, Ricono JM, Wagner B, Kim NH, Bhandari B, Choudhury GG, Abboud HE. Angiotensin II-induced ERK1/ERK2 activation and protein synthesis are redox-dependent in glomerular mesangial cells. Biochem J 381: 231-239, 2004.
12. Grande MT, Pérez-Barriocanal F, López-Novoa JM. Role of inflammation in tubulo-interstitial damage associated to obstructive nephropathy. J Inflamm 7: 19, 2010.
13. Greenawalt JW. The isolation of outer and inner mitochondrial membranes. Methods Enzymol 31: 310-323, 1974.
14. Holick MF. Vitamin D for health and in chronic kidney disease. Semin Dial 18: 266-275, 2005.
15. Hruska KA, Guo G, Wozniak M, et al. Osteogenic protein-1 prevents renal fibrogenesis associated with ureteral obstruction. Am J Physiol Renal Physiol 279: F130-F143, 2000.
16. Husain K, Ferder L, Mizobuchi M, Finch J, Slatopolsky E. Combination therapy with paricalcitol and enalapril ameliorates cardiac oxidative injury in uremic rats. Am J Nephrol 29: 465-472, 2009.
17. Husain K, Suarez E, Isidro A, Ferder L. Effects of paricalcitol and enalapril on atherosclerotic injury in mouse aortas. Am J Nephrol 32: 296-304, 2010.
18. Ichikawa I, Brenner BM. Local intrarenal vasoconstrictor-vasodilator interactions in mild partial ureteral obstruction. Am J Physiol Renal Fluid Electrolyte Physiol 236: F131-F140, 1979.
19. Kim R, Tanabe K, Emi M, Uchida Y, Inoue H, Toge T. Inducing cancer cell death by targeting transcription factors. Anticancer Drugs 14: 3-11, 2003.
20. Klahr S, Morrissey J. Obstructive nephropathy and renal fibrosis. Am J Physiol Renal Physiol 283: F861-F875, 2002.
21. Klahr S. Urinary tract obstruction. Semin Nephrol 21: 133-145, 2001.
22. Li M, Batuman V. Vitamin D: a new hope for chronic kidney disease? Kidney Int 76: 1219-1221, 2009.
23. Manucha W, Carrizo L, Ruete C, Molina H, Vallés P. Angiotensin II type I antagonist on oxidative stress and heat shock protein 70 (HSP 70) expression in obstructive nephropathy. Cell Mol Biol (Noisy-le-grand) 51: 547-555, 2005.
24. Manucha W. Biochemical-molecular markers in unilateral ureteral obstruction. Biocell 31: 1-12, 2007.
25. Masson PJ. AFIP modification. J Techn Methods 12: 75-90, 1929.
26. Møller JC, Jørgensen TM, Mortensen J. Proximal tubular atrophy: qualitative and quantitative structural changes in chronic obstructive nephropathy in the pig. Cell Tissue Res 244: 479-491, 1986.
27. Montezano AC, Burger D, Ceravolo GS, Yusuf H, Montero M, Touyz RM. Novel Nox homologues in the vasculature: focusing on Nox4 and Nox5. Clin Sci (Lond) 120: 131-141, 2011.
28. Morrissey J, Hruska K, Guo G, Wang S, Chen Q, Klahr S. Bone morphometric protein-7 improves renal fibrosis and accelerates the return of renal function. J Am Soc Nephrol 13: S14-S21, 2002.
29. Narvaez CJ, Zinser G, Welsh J. Functions of 1alpha,25-dihydroxyvita-min D(3) in mammary gland: from normal development to breast cancer. Steroids 66: 301-308, 2001.
30. O'Beirne GB, Williams DC. The subcellular location in rat kidney of the peripheral benzodiazepine acceptor. Eur J Biochem 175: 413-421, 1988.
31. Pedzik A, Paradowski M, Rysz J. Oxidative stress in nephrology. Pol Merkur Lekarski 28: 56-60, 2010.
32. Puri TS, Shakaib MI, Chang A, Mathew L, Olayinka O, Minto AW, Sarav M, Hack BK, Quigg RJ. Chronic kidney disease induced in mice by reversible unilateral ureteral obstruction is dependent on genetic background. Am J Physiol Renal Physiol 298: F1024-F1032, 2010.
33. Querings K, Girndt M, Geisel J, Georg T, Tilgen W, Reichrath J. 25-Hydroxyvitamin D deficiency in renal transplant recipients. J Clin Endocrinol Metab 91: 526-529, 2006.
34. Rachez C, Freedman LP. Mechanisms of gene regulation by vitamin D(3) receptor. A network of coactivator interactions. Gene 246: 9-21, 2000.
35. Rinaldi Tosi ME, Bocanegra V, Manucha W, Gil Lorenzo A, Vallés PG. The Nrf2-Keap1 cellular defense pathway and heat shock protein 70 (Hsp70) response. Role in protection against oxidative stress in early neonatal unilateral ureteral obstruction (UUO). Cell Stress Chaperones 16: 57-68, 2011.
36. Sachse A, Wolf G. Angiotensin II-induced reactive oxygen species and the kidney. J Am Soc Nephrol 18: 2439-2446, 2007.
37. Silvagno F, De Vivo E, Attanasio A, Gallo V, Mazzucco G, Pescar-mona G. Mitochondrial localization of vitamin D receptor in human platelets and differentiated megakaryocytes. PLos One 5: e8670, 2010.
38. Smith JM, Stablein DM, Munoz R, Hebert D, McDonald RA. Contributions of the Transplant Registry: The 2006 Annual Report of the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS). Pediatr Transplant 11: 366-373, 2007.
39. Tan X, He W, Liu Y. Combination therapy with paricalcitol and tran-dolapril reduces renal fibrosis in obstructive nephropathy. Kidney Int 76: 1248-1257, 2009.
40. Tan X, Li Y, Liu Y. Paricalcitol attenuates renal interstitial fibrosis in obstructive nephropathy. J Am Soc Nephrol 17: 3382-3393, 2006.
41. Tan X, Wen X, Liu Y. Paricalcitol inhibits renal inflammation by promoting vitamin D receptor-mediated sequestration of NF-kappaB signaling. J Am Soc Nephrol 19: 1741-1752, 2008.
42. Wang XX, Jiang T, Shen Y, Santamaria H, Solis N, Arbeeny C, Levi M. Vitamin D receptor agonist doxercalciferol modulates dietary fat-induced renal disease and renal lipid metabolism. Am J Physiol Renal Physiol 300: F801-F810, 2011.
43. Zhang Y, Kong J, Deb DK, Chang A, Li YC. Vitamin D receptor attenuates renal fibrosis by suppressing the renin-angiotensin system. J Am Soc Nephrol 21: 966-973, 2010.